What is the maximum recommended dose of Lokelma (sodium zirconium cyclosilicate) for patients with chronic kidney disease?

Maximum Lokelma Dose for CKD Patients

The maximum recommended dose of Lokelma (sodium zirconium cyclosilicate) for CKD patients is 15 g once daily during maintenance therapy. 1

Dosing Algorithm Based on CKD Status

For Non-Dialysis CKD Patients

Initial Treatment Phase (up to 48 hours):

• Start with 10 g three times daily for up to 48 hours 1
• This applies regardless of CKD stage

Maintenance Phase:

• Standard starting dose: 10 g once daily 1
• Dose range: 5 g every other day to 15 g daily (this is your ceiling) 1
• Titrate in 5 g increments at intervals of 1 week or longer based on serum potassium levels 1
• Monitor potassium and adjust accordingly—decrease or discontinue if potassium falls below target range 1

For CKD Patients on Chronic Hemodialysis

Administer ONLY on non-dialysis days 1

Starting dose:

• 5 g once daily on non-dialysis days (standard) 1
• OR 10 g once daily on non-dialysis days if serum potassium >6.5 mEq/L 1

Maintenance range:

• 5 g to 15 g once daily on non-dialysis days (15 g is the maximum) 1
• Assess serum potassium after one week following initiation or dose adjustment 1
• Base adjustments on pre-dialysis potassium after the long interdialytic interval 1

Clinical Evidence Supporting These Doses

The HARMONIZE-OLE study demonstrated that most patients maintained normokalemia for up to 11 months with a median daily dose of 10 g (range 2.5-15 g), with 15 g representing the upper boundary tested 2. Long-term safety data from open-label trials showed that patients across all CKD stages, including those with eGFR <30 mL/min/1.73 m², achieved and maintained normokalemia with doses up to 15 g daily 3.

Critical Safety Considerations

Edema risk increases with higher doses:

• In non-dialysis patients, edema occurred in 4.4% at 5 g, 5.9% at 10 g, and 16.1% at 15 g compared to 2.4% with placebo 1
• Each 5 g dose contains approximately 400 mg of sodium 1
• Monitor closely for fluid overload, especially in heart failure or advanced CKD 1

Hypokalemia risk:

• 4.1% of non-dialysis patients developed hypokalemia (<3.5 mEq/L) in clinical trials 1
• In hemodialysis patients, 5% developed pre-dialysis hypokalemia, with 3% dropping below 3.0 mEq/L 1
• Patients on dialysis are particularly vulnerable during acute illness (decreased oral intake, diarrhea) 1

Practical Pitfalls to Avoid

1. Never exceed 15 g daily—this is the FDA-approved maximum with established safety data 1

2. Don't give Lokelma on dialysis days for hemodialysis patients—it's only for non-dialysis days 1

3. Separate from other oral medications by 2 hours before or after Lokelma due to potential pH-dependent absorption interactions 1

4. Avoid in severe constipation or bowel obstruction—Lokelma has not been studied in these conditions and may worsen gastrointestinal problems 1

5. Monitor more frequently at 15 g dose—the edema risk nearly quadruples compared to lower doses, requiring vigilant assessment for fluid retention 1